317 related articles for article (PubMed ID: 25921286)
1. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
Zhong C; Wu JD; Fang MM; Pu LY
Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
[TBL] [Abstract][Full Text] [Related]
2. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
4. Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection.
Lu HF; Yuan WP; Li M; Huang Q; Liu JP; Li LQ; Zhong JH
Tumour Biol; 2015 Jul; 36(7):4937-8. PubMed ID: 26025114
[No Abstract] [Full Text] [Related]
5. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
6. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
7. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
10. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
11. CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.
Yiming L; Yunshan G; Bo M; Yu Z; Tao W; Gengfang L; Dexian F; Shiqian C; Jianli J; Juan T; Zhinan C
Oncotarget; 2015 Dec; 6(39):42019-27. PubMed ID: 26503471
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
13. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
14. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma.
Chan AW; Tong JH; Chan SL; Lai PB; To KF
Histopathology; 2014 Jun; 64(7):935-50. PubMed ID: 24506513
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
16. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
17. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
18. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.
Yeh CT; Kuo CJ; Lai MW; Chen TC; Lin CY; Yeh TS; Lee WC
BMC Cancer; 2009 Sep; 9():324. PubMed ID: 19744348
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
20. CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis.
Peng F; Li H; You Q; Li H; Wu D; Jiang C; Deng G; Li Y; Li Y; Wu Y
Biomed Res Int; 2017; 2017():5019367. PubMed ID: 28386553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
